Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B. Gelas-Dore

Ibrutinib in Relapse or Refractory Primary CNS and Vitreo-Retinal Lymphoma. Results of the Primary End-Point of the I Loc Phase Ii Study From the Lysa and the French Loc Network.

Hematological Oncology

English

Related publications

Temozolomide in Relapse/Refractory Primary Vitreo-Retinal Lymphoma (R/R Pvrl): A Simple, Cheap, Effective and Well Tolerated Treatment. Result of the Largest Study on R/R Pvrl, From the Loc Network

Hematological Oncology

English

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Hematological Oncology

English

The 5-Year Follow-Up Results of the C5r Protocol With Rituximab and Intrathecal Liposomal Cytarabine for Primary CNS Lymphoma: A Prospective Phase 2 Study of the Lysa

Hematological Oncology

English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology

English

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology

English

Early Relapses in Primary CNS Lymphoma After Response to Polychemotherapy Without Intraventricular Treatment: Results of a Phase II Study

Journal of Neuro-Oncology

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Characteristics and Natural History of Primary Vitreoretinal Lymphoma (PVL) Compared to the Primary Lymphoma of the CNS (PCNSL)

Hematological Oncology

English

LOC Syndrome

2020

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B. Gelas-Dore

Ibrutinib in Relapse or Refractory Primary CNS and Vitreo-Retinal Lymphoma. Results of the Primary End-Point of the I Loc Phase Ii Study From the Lysa and the French Loc Network.

Related publications

Temozolomide in Relapse/Refractory Primary Vitreo-Retinal Lymphoma (R/R Pvrl): A Simple, Cheap, Effective and Well Tolerated Treatment. Result of the Largest Study on R/R Pvrl, From the Loc Network

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

The 5-Year Follow-Up Results of the C5r Protocol With Rituximab and Intrathecal Liposomal Cytarabine for Primary CNS Lymphoma: A Prospective Phase 2 Study of the Lysa

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Early Relapses in Primary CNS Lymphoma After Response to Polychemotherapy Without Intraventricular Treatment: Results of a Phase II Study

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Characteristics and Natural History of Primary Vitreoretinal Lymphoma (PVL) Compared to the Primary Lymphoma of the CNS (PCNSL)

LOC Syndrome